246
Views
26
CrossRef citations to date
0
Altmetric
Reviews

The pediatric sepsis biomarker risk model: potential implications for sepsis therapy and biology

, &

References

  • Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348(16):1546-54
  • Hanna W, Wong HR. Pediatric sepsis: challenges and adjunctive therapies. Crit Care Clin 2013;29(2):203-22
  • Cohen J. The immunopathogenesis of sepsis. Nature 2002;420(6917):885-91
  • Iskander KN, Osuchowski MF, Stearns-Kurosawa DJ, et al. Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev 2013;93(3):1247-88
  • Samraj RS, Zingarelli B, Wong HR. Role of biomarkers in sepsis care. Shock 2013;40(5):358-65
  • Wong HR, Salisbury S, Xiao Q, et al. The pediatric sepsis biomarker risk model. Crit Care 2012;16(5):R174
  • Wong HR, Weiss SL, Giuliano JS Jr, et al. Testing the prognostic accuracy of the update pediatric sepsis biomarker risk model. PLoS One 2014;9:e86242
  • Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011;12(2):165-73
  • Wong HR. Genome-wide expression profiling in pediatric septic shock. Pediatr Res 2013;73(4 Pt 2):564-9
  • Wong HR, Lindsell CJ, Pettila V, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med 2014;42(4):781-9
  • Lord SJ, Rajotte RV, Korbutt GS, Bleackley RC. Granzyme B: a natural born killer. Immunol Rev 2003;193:31-8
  • Napoli AM, Fast LD, Gardiner F, et al. Increased granzyme levels in cytotoxic T lymphocytes are associated with disease severity in emergency department patients with severe sepsis. Shock 2012;37(3):257-62
  • Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006;6(11):813-22
  • Freishtat RJ, Natale J, Benton AS, et al. Sepsis alters the megakaryocyte-platelet transcriptional axis resulting in granzyme B-mediated lymphotoxicity. Am J Respir Crit Care Med 2009;179(6):467-73
  • Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 2005;62(6):670-84
  • Garrido C, Brunet M, Didelot C, et al. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006;5(22):2592-601
  • Jacquier-Sarlin MR, Fuller K, Dinh-Xuan AT, et al. Protective effects of hsp70 in inflammation. Experientia 1994;50(11-12):1031-8
  • Jaattela M, Wissing D, Bauer PA, Li GC. Major heat shock protein hsp70 protects tumor cells from tumor necrosis factor cytotoxicity. EMBO J 1992;11(10):3507-12
  • Luong M, Zhang Y, Chamberlain T, et al. Stimulation of TLR4 by recombinant HSP70 requires structural integrity of the HSP70 protein itself. J Inflamm (Lond) 2012;9:11
  • Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008;8(4):279-89
  • McConnell KW, Fox AC, Clark AT, et al. The role of heat shock protein 70 in mediating age-dependent mortality in sepsis. J Immunol 2011;186(6):3718-25
  • Bruemmer-Smith S, Stuber F, Schroeder S. Protective functions of intracellular heat-shock protein (HSP) 70-expression in patients with severe sepsis. Intensive Care Med 2001;27(12):1835-41
  • Ziegler TR, Ogden LG, Singleton KD, et al. Parenteral glutamine increases serum heat shock protein 70 in critically ill patients. Intensive Care Med 2005;31(8):1079-86
  • Pittet JF, Lee H, Morabito D, et al. Serum levels of Hsp 72 measured early after trauma correlate with survival. J Trauma 2002;52(4):611-17. discussion 617
  • Wheeler DS, Fisher LE Jr, Catravas JD, et al. Extracellular hsp70 levels in children with septic shock. Pediatr Crit Care Med 2005;6(3):308-11
  • Rider P, Carmi Y, Voronov E, Apte RN. Interleukin-1a. Semin Immunol 2013;25(6):430-8
  • McCarthy DA, Clark RR, Bartling TR, et al. Redox control of the senescence regulator interleukin-1alpha and the secretory phenotype. J Biol Chem 2013;288(45):32149-59
  • Joosten LA, Van De Veerdonk FL, Vonk AG, et al. Differential susceptibility to lethal endotoxaemia in mice deficient in IL-1alpha, IL-1beta or IL-1 receptor type I. APMIS 2010;118(12):1000-7
  • Harada A, Mukaida N, Matsushima K. Interleukin 8 as a novel target for intervention therapy in acute inflammatory diseases. Mol Med Today 1996;2(11):482-9
  • Miyoshi T, Yamashita K, Arai T, et al. The role of endothelial interleukin-8/NADPH oxidase 1 axis in sepsis. Immunology 2010;131(3):331-9
  • Ware LB, Koyama T, Zhao Z, et al. Biomarkers of lung epithelial injury and inflammation distinguish severe sepsis patients with acute respiratory distress syndrome. Crit Care 2013;17(5):R253
  • Wong HR, Cvijanovich N, Wheeler DS, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008;178(3):276-82
  • Calfee CS, Thompson BT, Parsons PE, et al. Plasma interleukin-8 is not an effective risk stratification tool for adults with vasopressor-dependent septic shock. Crit Care Med 2010;38(6):1436-41
  • Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol 1996;59(1):61-6
  • Standiford TJ, Kunkel SL, Lukacs NW, et al. Macrophage inflammatory protein-1 alpha mediates lung leukocyte recruitment, lung capillary leak, and early mortality in murine endotoxemia. J Immunol 1995;155(3):1515-24
  • Kobayashi M, Takahashi H, Sanford AP, et al. An increase in the susceptibility of burned patients to infectious complications due to impaired production of macrophage inflammatory protein 1 alpha. J Immunol 2002;169(8):4460-6
  • Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002;13(6):455-81
  • O’Grady NP, Tropea M, Preas HL 2nd, et al. Detection of macrophage inflammatory protein (MIP)-1alpha and MIP-1beta during experimental endotoxemia and human sepsis. J Infect Dis 1999;179(1):136-41
  • Lahrtz F, Piali L, Spanaus KS, et al. Chemokines and chemotaxis of leukocytes in infectious meningitis. J Neuroimmunol 1998;85(1):33-43
  • Okamoto T, Akaike T, Suga M, et al. Activation of human matrix metalloproteinases by various bacterial proteinases. J Biol Chem 1997;272(9):6059-66
  • Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007;82(6):1375-81
  • Solan PD, Dunsmore KE, Denenberg AG, et al. A novel role for matrix metalloproteinase-8 in sepsis. Crit Care Med 2012;40(2):379-87
  • Lauhio A, Hastbacka J, Pettila V, et al. Serum MMP-8, -9 and TIMP-1 in sepsis: high serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines. Pharmacol Res 2011;64(6):590-4
  • Vandenbroucke RE, Dejonckheere E, Van Lint P, et al. Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases. J Neurosci 2012;32(29):9805-16
  • Wynn J, Cornell TT, Wong HR, et al. The host response to sepsis and developmental impact. Pediatrics 2010;125(5):1031-41
  • Barsness KA, Bensard DD, Partrick DA, et al. IL-1beta induces an exaggerated pro- and anti-inflammatory response in peritoneal macrophages of children compared with adults. Pediatr Surg Int 2004;20(4):238-42
  • Barsness KA, Bensard DD, Partrick DA, et al. Endotoxin induces an exaggerated interleukin-10 response in peritoneal macrophages of children compared with adults. J Pediatr Surg 2004;39(6):912-15. discussion 912-5
  • Mariotti M, Castiglioni S, Bernardini D, Maier JA. Interleukin 1 alpha is a marker of endothelial cellular senescent. Immun Ageing 2006;3:4
  • Kumar S, Vinci JM, Millis AJ, Baglioni C. Expression of interleukin-1 alpha and beta in early passage fibroblasts from aging individuals. Exp Gerontol 1993;28(6):505-13
  • Boomer JS, Shuherk-Shaffer J, Hotchkiss RS, Green JM. A prospective analysis of lymphocyte phenotype and function over the course of acute sepsis. Crit Care 2012;16(3):R112
  • Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13(12):862-74
  • Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348(2):138-50
  • Wong HR, Weiss SL, Giuliano JS Jr, et al. The temporal version of the pediatric sepsis biomarker risk model. PLoS One 2014;9(3):e92121
  • Wynn JL, Neu J, Moldawer LL, Levy O. Potential of immunomodulatory agents for prevention and treatment of neonatal sepsis. J Perinatol 2009;29(2):79-88
  • Abulebda K, Cvijanovich NZ, Thomas NJ, et al. Post-ICU Admission Fluid Balance and Pediatric Septic Shock Outcomes: a Risk-Stratified Analysis. Crit Care Med 2014;42(2):397-403
  • Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004;32(11):2173-82
  • Mussap M, Noto A, Cibecchini F, Fanos V. The importance of biomarkers in neonatology. Semin Fetal Neonatal Med 2013;18(1):56-64
  • Noto A, Mussap M, Fanos V. Is H NMR metabolomics becoming the promising early biomarker for neonatal sepsis and for monitoring the antibiotic toxicity? J Chemother 2013. [Epub ahead of print]
  • Mickiewicz B, Vogel HJ, Wong HR, Winston BW. Metabolomics as a novel approach for early diagnosis of pediatric septic shock and its mortality. Am J Respir Crit Care Med 2013;187(9):967-76

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.